Synthetic Biologics

$0.546
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0644 (-9.99%) Today
-$0.0341 (-5.88%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell SYN and other stocks, options, and ETFs commission-free!

About SYN

Synthetic Biologics, Inc., also called Synthetic Biologics, is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD. The listed name for SYN is Synthetic Biologics, Inc.

CEO
Steven A. Shallcross
Employees
11
Headquarters
Rockville, Maryland
Founded
2001
Market Cap
61.35M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
19.95M
High Today
$0.64
Low Today
$0.545
Open Price
$0.6228
Volume
14.59M
52 Week High
$1.70
52 Week Low
$0.2522

SYN Earnings

-$0.31
-$0.21
-$0.10
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.08 per share
Actual
-$0.14 per share
Replay Earnings Call

You May Also Like

IDOG
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure